Bahram Valamehr - Jul 29, 2024 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role: Chief R&D Officer
Signature: /s/ Cindy R. Tahl, as Attorney-in-Fact
Stock symbol: FATE
Transactions as of: Jul 29, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/31/2024, 06:05 PM
Previous filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FATE	Common Stock	Award	$0	+200K	+126.53%	$0.00	358K	Jul 29, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were granted pursuant to a restricted stock unit award. 100,000 of the units are subject to time-based vesting and 100,000 of the units are subject to performance-based vesting. 25,000 time-based units will vest on August 1, 2025 and 75,000 time-based units will vest on August 1, 2026, so long as the reporting person continues to serve as an employee of the issuer through each vesting date. Subject to the achievement of specified late-stage clinical and regulatory milestones of the issuer on or before July 29, 2028, half of the performance-based units will vest one year after the achievement of two of three of the milestones, and the remaining 50,000 of the performance-based units will vest on the date one year after the achievement of all three of the milestones, in each case subject to the grantee's continued employment with the issuer through each such vesting date.

Content

These shares were granted pursuant to a restricted stock unit award. 100,000 of the units are subject to time-based vesting and 100,000 of the units are subject to performance-based vesting. 25,000 time-based units will vest on August 1, 2025 and 75,000 time-based units will vest on August 1, 2026, so long as the reporting person continues to serve as an employee of the issuer through each vesting date. Subject to the achievement of specified late-stage clinical and regulatory milestones of the issuer on or before July 29, 2028, half of the performance-based units will vest one year after the achievement of two of three of the milestones, and the remaining 50,000 of the performance-based units will vest on the date one year after the achievement of all three of the milestones, in each case subject to the grantee's continued employment with the issuer through each such vesting date.